About ARV-110ARV-110 is an investigational orally bioavailable PROTAC® protein degrader designed to selectively target and degrade the androgen receptor (AR).

Arvinas PROTAC® Protein Degrader Bavdegalutamide (ARV-110) Continues to Demonstrate Clinical Benefit in Men with Metastatic Castration-Resistant Prostate Cancer ...

NEW HAVEN, Conn., May 13, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ...

- Clear efficacy signal with two ongoing confirmed PSA responses, including one associated with a confirmed RECIST response -- Data represent the ...

NEW HAVEN, Conn., March 25, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biopharmaceutical company creating a new class of therapies ...

Polycystic ovary syndrome is a common endocrine disorder in women of reproductive age and characterized by obesity, insulin resistance and renal injury.

Arvinas Inc (NASDAQ: ARVN) announced the presentation of new data from completed Phase 1 dose-escalation and ongoing Phase 2 ARDENT expansion cohort with bavdegalutamide (ARV-110). The data were ...

New Haven biotech Arvinas Inc. released early data on Wednesday suggesting its experimental drug ARV-110 was effective on a hard-to-treat type of prostate cancer that’s been resistant to other ...

* ARVINAS INC - ANNOUNCED UPDATED DATA FROM DOSE ESCALATION PORTION OF COMPANY'S PHASE 1/2 CLINICAL TRIAL OF ARV-110 * ARVINAS INC - UPDATED DATA SHOWS AR DEGRADATION DEMONSTRATES THAT ARV-110 IS ...

– ARV-471 demonstrates evidence of anti-tumor activity, and potential for best-in-class safety, and estrogen receptor (ER) degradation profile and robust efficacy signals in a heavily pretreated ...